Bell Lab

John Bell profile picture

Contact Information

John Bell, PhD
613 737-7700 70333

501 Smyth Road, Box 926
Ottawa, ON K1H 8L6

ORCID logo


Selected Publications

Kwame Twumasi-Boateng, Jessica L. Pettigrew, Y. Y. Eunice Kwok, John C. Bell & Brad H. Nelson. Oncolytic viruses as engineering platforms for combination immunotherapy. Nature Reviews Cancer. Published online: 25 April 2018. doi:10.1038/s41568-018-0009-4. Free full text.

Bourgeois-Daigneault MC, Roy DG, Aitken AS, El Sayes N, Martin NT, Varette O, Falls T, St-Germain LE, Pelin A, Lichty BD, Stojdl DF, Ungerechts G, Diallo JS and Bell JC. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Sci Transl Med. 2018 Jan 3;10(422). Free full text.

Rozanne Arulanandam, Cory Batenchuk, Fernando A. Angarita, Kathryn Ottolino-Perry, Sophie Cousineau, Amelia Mottashed, Emma Burgess, Theresa J. Falls, Naomi De Silva, Jovian Tsang, Grant A. Howe, Marie-Claude Bourgeois-Daigneault, David P. Conrad, Manijeh Daneshmand, Caroline J. Breitbach, David H. Kirn, Leda Raptis, Subash Sad, Harold Atkins, Michael S. Huh, Jean-Simon Diallo, Brian Lichty, Carolina S. Ilkow, Fabrice Le Boeuf, Christina L. Addison, J. Andrea Mc Cart and John C. Bell. VEGF-mediated induction of PRD1-BF1/Blimp1 expression sensitizes tumour vasculature to oncolytic virus infection. Cancer Cell. 2015 Aug 10;28(2):210-24. 

Carolina S. Ilkow, Monique Marguerie, Cory Batenchuk, Justin Mayer, Daniela Ben Neriah, Sophie Cousineau, Theresa Falls, Victoria Jennings, Meaghan Boileau, David Bellamy1, Donald Bastin1, Christiano Tanese de Souza1, Almohanad Alkayyal1, Jiging Zhang, Fabrice LeBoeuf1, Rozanne Arulanandam, Lawton Stubbert, Padma Sampath, Steve Thorne4, Piriya Paramanthan5, Avijit Chatterjee5, Robert M. Strieter, Marie Burdick, Christina Addison David F. Stojdl, Harold L. Atkins, Rebecca Auer, , Jean-Simon Diallo, Brian Lichty, and John C. Bell. Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nat Med. 2015 May;21(5):530-6.

Brian D. Lichty, Caroline J. Breitbach, David F. Stojdl, & John C. Bell. Going viral with cancer immunotherapy. Nature Reviews Cancer. 2014 03 July.

Fabrice Le Bœuf*, Cory Batenchuk*, Markus Vähä-Koskela, Sophie Breton, Dominic Roy, Chantal Lemay, Julie Cox, Hesham Abdelbary, Theresa Falls, Girija Waghray, Harold Atkins, David Stojdl, Jean-Simon Diallo, Mads Kaern, John Bell. Model-based Rational Design of an Oncolytic Virus with Improved Therapeutics Potential. Nature Communications 2013 Jun 14;4:1974.

Heo, J.,Reid, T., Ruo, L., Breitbach, C.,Rose, S., Bloomston, M., Cho, M., Lim, H.Y., Chung, H.C., Kim, C.W., Burke, J.,Lencioni, R., Hickman, T., Moon, A., Lee, Y.S., Kim, M.K., Daneshmand, M., Dubois, K., Longpre, L., Ngo, M., Rooney, C., Bell, J.C.,Rhee,B-G., Patt, R., Hwang, T-H., Kirn, D.H., (2013) Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX 594 in liver cancer. Nat Med. 2013 Mar;19(3):329-36.

All Other Publications

Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy.(2012) Nature Biotechnology 30:658-70.

CJ Breitbach, J Burke, D Jonker, J Stephenson, AR Haas, LQM Chow, J Nieva, TH Hwang, A Moon, R Patt, A Pelusio, F LeBoeuf, J Burns, L Evgin, N De Silva, S Cvancic, T Robertson, JE Je, YS Lee, K Parato, JS Diallo, AFenster, M Daneshmand, JC Bell and DH Kirn. (2011)Intravenous delivery of a cancer-targeted poxvirus results in tumour-specific replication, transgene expression and efficacy in cancer patients. Nature 477: 99–102.

Breitbach CJ, De Silva NS, Falls TJ, Aladl U, Evgin L. Paterson J, Sun YY, Roy DG, Rintoul JL, Daneshamand M. Parato K, Stanford MM, Lichty BR, Fenster A, Kirn D, Atkins H, Bell JC.(2011) Targeting Tumor Vasculature with an Oncolytic Virus. Molecular Therapy 19:886-94.

Lemay CG, Rintoul JL, Kus A, Paterson JM, Garcia V, Falls TJ, Ferreira L, Bridle BW, Conrad DP, Tang VA, Diallo JS, Arulanandam R, Le Boeuf F, Garson K, Vanderhyden BC, Stojdl DF, Lichty BD, Atkins HL, Parato KA, Bell JC*, Auer RC*. (2012) Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. Mol Ther.20(9):1791-9. Co-senior authors*

Breitbach CJ, Arulanandam R, De Silva N, Thorne SH, Patt R, Daneshmand M, Moon A, Ilkow C, Burke J, Hwang TH, Heo J, Cho M, Chen H, Angarita FA, Addison C, McCart JA, Bell JC, Kirn DH. Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans. Cancer Res. 2013 Feb 15;73(4):1265-75.

Muik A, Stubbert LJ, Jahedi RZ, Geiß Y, Kimpel J, Dold C, Tober R, Volk A, Klein S, Dietrich U, Yadollahi B, Falls T, Miletic H, Stojdl D, Bell JC, von Laer D. Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity and enhance oncolytic potency. Cancer Res. 2014 Jul 1;74(13):3567-78.

Bell J. Oncolytic viruses: immune or cytolytic therapy? Mol Ther. 2014 Jul;22(7):1231-2.

Listings from The Ottawa Hospital Library

This lists the 5 most recent publications in The Ottawa Hospital's Library database from this lab.This database only starts tracking a researcher's publications once they start working at the Ottawa Hospital Research Institute.
More publications may be available in The Ottawa Hospital Library database.

PubMed Listings

For more publications use this PubMed ID link.